High interest costs are squeezing governments and households, yet healthcare remains a non‑discretionary spend that people rarely cut. That combination keeps attention on financially solid medical businesses with resilient demand for treatments, equipment and services. The opportunity is clear for investors who want exposure to this theme without having to sift through hundreds of tickers. This article spotlights three of the strongest healthcare stocks from our curated screener.
The three stocks highlighted below are just a starting sample, since the full Best Healthcare Stocks screen surfaced 36 more companies with equally compelling narratives that are not covered in this article.
To identify and analyze the highest conviction opportunities across providers, equipment makers, pharma, biotech and healthcare tech, head straight into the Best Healthcare Stocks screener .
GeneDx Holdings (WGS)
GeneDx Holdings brings the Best Healthcare Stocks theme right into the pediatric clinic, using large scale genomic testing and AI tools to turn rare disease diagnosis into a routine part of frontline care. This is exactly where reimbursement pressure and growth hopes collide.
"Rapid long-term reimbursement gains from Medicaid and commercial payers are unlikely to be sustainable as government cost-containment efforts intensify in response to rising healthcare spending, increasing the risk that reimbursement rates for advanced diagnostics will decline and directly pressure GeneDx's future revenue growth and gross margins."
What happens to GeneDx's margins and testing volumes if that unseen pricing squeeze lands harder or softer than the market currently assumes?
That pricing fork in the road is exactly what the full narrative for GeneDx Holdings unpacks, showing where accelerating test volumes could decouple from reimbursement risk.
Kiniksa Pharmaceuticals International (KNSA)
Kiniksa Pharmaceuticals International is a focused biopharma player in the Best Healthcare Stocks theme, built around ARCALYST for recurrent pericarditis and a small pipeline of immunology assets. The business generated about US$840.8 million from therapeutic medicines and has a market value near US$6.2b.
"Significant expansion opportunities for ARCALYST remain, as market penetration into the recurrent pericarditis population is still only 15%, with a large additional segment (first recurrence patients) representing another untapped 26,000 patients."
The real swing factor is what happens to long term earnings power if that early growth runway meets one hard to see constraint.
If that constraint is what really caps earnings power, the full narrative for Kiniksa Pharmaceuticals International shows how Kiniksa Pharmaceuticals International could still accelerate value as the pericarditis market matures.
Immunocore Holdings (IMCR)
Immunocore Holdings plugs into the Best Healthcare Stocks theme through KIMMTRAK, a commercial immunotherapy for rare eye cancer, while its T-cell receptor platform is being advanced into broader melanoma settings and new disease areas that could influence how future oncology revenue is earned.
Immunocore Holdings develops immunotherapies across cancer, infectious disease and autoimmune conditions, generating about US$430.8 million from immunotherapies and carrying a market value near US$1.5b.
"Expansion of KIMMTRAK into additional melanoma settings through the TEBE-AM and ATOM Phase III programs, which together target roughly 4,000 second-line-plus cutaneous melanoma patients and 1,200 high-risk adjuvant uveal melanoma patients, could shift Immunocore Holdings from a rare disease revenue base toward a broader melanoma franchise that supports higher long term sales and operating leverage."
An important consideration is how pressure on future earnings quality may shape what that wider melanoma footprint is ultimately worth.
That trade off is exactly where the full narrative for Immunocore Holdings shows whether current melanoma momentum is masking bigger upside or underpricing long term execution risk.
Seeking Fresh Alternatives Before They Fly
Fresh breakouts and early momentum often get caught quickly. Scan these curated ideas before the crowd notices, while the data still matters, and get in early.
-
Target reliable cash generators and stay focused on balance sheet strength by running the list of solid balance sheet and fundamentals (25 results) before those sturdier businesses stop trading under the radar.
-
Hunt for early-stage compounding potential by checking the 20 high quality undiscovered gems that pair cleaner financials with business models most investors have not fully priced in yet.
-
Ride the shift toward automation by reviewing the 92 robotics and automation stocks curated for companies building real-world robotics and factory tech before sentiment sends valuations flying.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
